drugset
drugset / Trial / NCT02472769

IBP-9414 for the Prevention of Necrotizing Enterocolitis

NCT02472769 ↗

Phase 2 Completed 120 enrolled Infant Bacterial Therapeutics
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.

Timeline

Start
2016-05-27
Primary completion
2017-08-07
Completion
2017-08-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator IBP-9414 Unknown — Oral

Indications

necrotizing enterocolitis